Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3106MR)

This product GTTS-WQ3106MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3106MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1240MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ14648MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ10939MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ14106MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ13661MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ14595MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ14677MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW